Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytokinetics R&D Day Spotlights Muscle Programs Beyond Heart Failure Drug

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Cytokinetics made headlines with its heart failure drug in May after Amgen elected in to its option on worldwide rights (except in Japan), but its pipeline – presented at an R&D day Sept. 18 – holds other assets that could be strong candidates from the young company. In particular, Cytokinetics’ early stage skeletal muscle candidate garnered excitement from Wall Street for its wider breadth of uses.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts